Company profile: Medesis Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical development leveraging AONYS, a buccal micro-emulsion platform enabling delivery of water-soluble actives across the blood-brain barrier, to develop orally administered candidates addressing unmet needs, including Nanolithium for Alzheimer's, NanoManganese for radiotherapy, NU01/NU02 for plutonium/cesium decorporation, and P42 for Huntington's.
Products and services
- AONYS: A micro-emulsion platform for buccal administration that facilitates the delivery of water-soluble pharmaceutical active ingredients across the blood-brain barrier
- P42: A peptide-based treatment for Huntington’s disease, delivered using the AONYS micro-emulsion to target brain cells and improve disease symptoms
- Nanolithium: A lithium-based formulation under development for Alzheimer’s disease that aims to modify disease progression and expand therapeutic usefulness addressing major unmet medical needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Medesis Pharma
NuSirt
HQ: United States
Website
- Description: Provider of biotechnology solutions developing a patented leucine-metformin combination designed to reduce the side effects of metformin while maintaining its effectiveness in controlling blood sugar levels in Type 2 diabetes patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuSirt company profile →
Jaguar Gene Therapy
HQ: United States
Website
- Description: Provider of AAV-based gene therapy candidates for severe genetic diseases, including JAG101, a preclinical therapy delivering the functional GALT gene via AAV9 for Type 1 galactosemia; JAG201, an investigational therapy targeting SHANK3-related disorders such as autism spectrum disorder and Phelan-McDermid syndrome; and JAG301, a preclinical therapy producing functional beta cells through transdifferentiation for Type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jaguar Gene Therapy company profile →
Bigfoot Biomedical
HQ: United States
Website
- Description: Provider of diabetes management solutions for insulin-requiring individuals, offering the Bigfoot Unity system that integrates with the FreeStyle Libre 2 sensor to provide insulin dose recommendations for multiple-daily-injection users, the Bigfoot Unity Mobile App for dosing and glucose data, and the Bigfoot Clinic Hub for clinician data review; adheres to security and privacy laws, including HIPAA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bigfoot Biomedical company profile →
GI Dynamics
HQ: United States
Website
- Description: Provider of endoscopically delivered medical devices for managing type 2 diabetes, obesity, and related metabolic diseases, including RESET, which creates a barrier in the small intestine to improve insulin resistance and glycemic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GI Dynamics company profile →
Alantos
HQ: United States
Website
- Description: Provider of chemistry-driven biopharmaceutical discovery and development of small molecule drugs for osteoarthritis, inflammation, and type II diabetes; offerings include tissue remodeling pathways for rheumatoid arthritis and a dipeptidyl peptidase IV inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alantos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Medesis Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Medesis Pharma
2.2 - Growth funds investing in similar companies to Medesis Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Medesis Pharma
4.2 - Public trading comparable groups for Medesis Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →